This is an aggregated industry headline. Read the full story at Drug Channels →
The Hidden Cost of 340B for Employers and Health Plans
By Adam J. Fein, Ph.D.For years, the controversy surrounding the 340B Drug Pricing Program has centered on hospitals, manufacturers, and contract pharmacies. But employers and health plans have become major participants in the program's economics-even though many don't realize it. The short video be
By Drug Channels
· Jul 8, 2026
· via Drug Channels
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Allergan Aesthetics on Tuesday welcomed Girls Inc. participants to a panel and tour at its Allergan Medical In…
The WeekFierceBiotech ↗
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, F…
The WeekBriefing
The newly approved Dexcom Stelo continuous glucose monitor opens access beyond diabetes management, prompting …